3 citations
,
November 2020 in “Phyton-international Journal of Experimental Botany” This review discusses the potential therapeutic applications of wedelolactone, a compound in Eclipta prostrata, for various chronic human diseases and reports no new clinical results.
January 2026 in “Frontiers in Pharmacology” This review highlights the potential of wedelolactone from the plant Wedelia Chinensis, summarizing its reported pharmacological effects, including anti-inflammatory, antiviral, antibacterial, antitumor, anti-osteoporosis activities, and organ protection based on existing in vitro and in vivo research findings.
January 2000 in “Time to knit” This article describes the extraction and characterization method for wedelolactone from Eclipta alba but presents no new clinical results.
June 2025 in “Universities Journal of Phytochemistry and Ayurvedic Heights” This study evaluated the wedelolactone content and antimicrobial activity of Eclipta alba and Wedelia chinensis extracts, finding a potential relationship between the concentration of wedelolactone and their in vitro antimicrobial effects against several pathogenic bacteria and yeast.
83 citations
,
October 2012 in “International Journal of Oncology” In this in vitro study, wedelolactone induced selective apoptosis in prostate cancer cells by inhibiting 5-Lox activity, suggesting it may have potential as a treatment for prostate cancer.